- Home
- PAPL vs REVB Comparison
PAPL vs REVB Comparison
Compare PAPL & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAPL
- REVB
- Stock Information
- Founded
- PAPL 2015
- REVB 2020
- Country
- PAPL Canada
- REVB United States
- Employees
- PAPL N/A
- REVB N/A
- Industry
- PAPL Finance: Consumer Services
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- PAPL Finance
- REVB Health Care
- Exchange
- PAPL Nasdaq
- REVB Nasdaq
- Market Cap
- PAPL 2.5M
- REVB 2.3M
- IPO Year
- PAPL 2023
- REVB N/A
- Fundamental
- Price
- PAPL $0.29
- REVB $3.08
- Analyst Decision
- PAPL Strong Buy
- REVB
- Analyst Count
- PAPL 2
- REVB 0
- Target Price
- PAPL $5.25
- REVB N/A
- AVG Volume (30 Days)
- PAPL 54.5K
- REVB 135.4K
- Earning Date
- PAPL 04-14-2025
- REVB 05-09-2025
- Dividend Yield
- PAPL N/A
- REVB N/A
- EPS Growth
- PAPL N/A
- REVB N/A
- EPS
- PAPL N/A
- REVB N/A
- Revenue
- PAPL $2,848,365.00
- REVB N/A
- Revenue This Year
- PAPL $22.95
- REVB N/A
- Revenue Next Year
- PAPL $29.98
- REVB N/A
- P/E Ratio
- PAPL N/A
- REVB N/A
- Revenue Growth
- PAPL 13.01
- REVB N/A
- 52 Week Low
- PAPL $0.18
- REVB $2.36
- 52 Week High
- PAPL $2.14
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- PAPL 43.64
- REVB 48.50
- Support Level
- PAPL $0.25
- REVB $2.92
- Resistance Level
- PAPL $0.31
- REVB $3.68
- Average True Range (ATR)
- PAPL 0.03
- REVB 0.37
- MACD
- PAPL 0.00
- REVB 0.07
- Stochastic Oscillator
- PAPL 52.78
- REVB 50.72
About PAPL Pineapple Financial Inc.
Pineapple Financial Inc is a Canada-based mortgage technology and brokerage company that provides mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. Through its data-driven systems together with cloud-based tools, it offers advantages in the Canadian mortgage industry relative to alternative mortgage broker arrangements and also provides back office services.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).